← Back to patent-cliff list
Atebimetinib
Tier C — Watch / tradeAtebimetinib
Immuneering Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MEK
Indications (approved)：Adenocarcinoma, Pancreatic cancer, 胰腺导管癌, Non-small cell lung cancer, 皮肤黑色素瘤, Solid tumour
Regional status
US
Phase III
2026-06-05
EU
Phase III
2026-06-05
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atebimetinib?
Approved indications include: Adenocarcinoma, Pancreatic cancer, 胰腺导管癌, Non-small cell lung cancer, 皮肤黑色素瘤, Solid tumour.
When does the Atebimetinib patent expire?
No public expiry year is available for Atebimetinib yet; this page updates once verified.
How do I get a quote for Atebimetinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29